Topics

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines and Lateral Canthal Lines

2019-11-12 18:25:15 | BioPortfolio

Summary

To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in participants with moderate to severe GL and/or LCL.

Study Design

Conditions

Glabellar Lines

Intervention

MT10109L

Location

Advanced Research Associates
Glendale
Arizona
United States
85308

Status

Enrolling by invitation

Source

Allergan

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-11-12T18:25:15-0500

Clinical Trials [123 Associated Clinical Trials listed on BioPortfolio]

MT10109L in the Treatment of Glabellar Lines

To evaluate the safety and efficacy of MT10109L in the treatment of glabellar lines (GL) in participants with moderate to severe GL.

MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines

To evaluate the safety and efficacy of MT10109L for the treatment of lateral canthal lines (LCL) with or without concurrent treatment of glabellar lines (GL) in participants with moderate ...

MT10109L in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines

To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate ...

MT10109L in the Treatment of Lateral Canthal Lines

To evaluate the safety and efficacy of MT10109L in the treatment of lateral canthal lines (LCL) in participants with moderate to severe LCL

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).

PubMed Articles [2800 Associated PubMed Articles listed on BioPortfolio]

Efficacy, Safety, and Subject Satisfaction After AbobotulinumtoxinA Treatment for Moderate to Severe Glabellar Lines.

The aesthetic use of botulinum toxins is widely accepted in routine treatment of glabellar lines.

Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial.

The FACE-Q patient-reported outcome assesses patient experiences/outcomes with aesthetic facial procedure. A recent trial of abobotulinumtoxinA (ASI, liquid-formulation) was the first to assess satisf...

Glabellar vertical line as a reference goal for anteroposterior maxillary position.

The aim of this study was to evaluate the use of glabellar vertical line (GVL) as the anteroposterior maxillary position goal.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects.

PrabotulinumtoxinA is a 900 kDa botulinum toxin type A produced by Clostridium botulinum.

OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.

Patient-reported outcomes are important measures of treatment benefit in facial aesthetic medicine.

Medical and Biotech [MESH] Definitions

Cell lines whose original growing procedure consisted being transferred (T) every 3 days and plated at 300,000 cells per plate (J Cell Biol 17:299-313, 1963). Lines have been developed using several different strains of mice. Tissues are usually fibroblasts derived from mouse embryos but other types and sources have been developed as well. The 3T3 lines are valuable in vitro host systems for oncogenic virus transformation studies, since 3T3 cells possess a high sensitivity to CONTACT INHIBITION.

The turning inward of the lines of sight toward each other.

Works consisting of graphic representations of objects or ideas by lines.

A thin membrane that lines the ventricles of the brain and the central canal of the SPINAL CORD.

A genus of SPONGES in the family Chalinidae characterized by unispicular secondary lines in the choanosomal skeleton.

More From BioPortfolio on "MT10109L in the Long-term, Open-label Treatment of Glabellar Lines and Lateral Canthal Lines"

Quick Search

Searches Linking to this Trial